Ignite Creation Date:
2025-12-24 @ 11:16 PM
Ignite Modification Date:
2026-01-10 @ 3:17 PM
Study NCT ID:
NCT04162756
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2021-10-14
First Post:
2019-11-11
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies
Sponsor:
Kite, A Gilead Company
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
KT-US-472-0118
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None